MAIA Biotechnology Publishes Preclinical Data Validating Second-Generation Ateganosine Prodrugs for Cancer Therapy in Nucleic Acids Research Journal.

MAIA Biotechnology has announced the publication of preclinical data in Nucleic Acids Research validating its second-generation ateganosine prodrugs for anticancer therapy. The lead compounds, MAIA-2021-20 and MAIA-2022-12, demonstrated strong anticancer efficacy and immune-memory responses in vivo. The company plans to advance at least one candidate into human clinical trials upon completion of required GLP-toxicity and other evaluations.

MAIA Biotechnology, Inc. (NYSE American: MAIA) has announced the publication of preclinical data in the leading open-access peer-reviewed scientific journal Nucleic Acids Research (NAR), validating its second-generation ateganosine prodrugs for anticancer therapy. The study, titled "Novel Telomere-Targeting Dual-Pharmacophore Dinucleotide Prodrugs for Anticancer Therapy," details the company's lead ateganosine (THIO)-derived second-generation prodrugs as promising new molecules in its strategy for enhancing cancer treatment and overcoming drug resistance [1].

The preclinical data demonstrated that the lead compounds, MAIA-2021-20 and MAIA-2022-12, exhibited strong anticancer efficacy and induced robust host immune-memory responses in vivo. The sequential combination of these prodrugs with an immune checkpoint inhibitor resulted in significantly lower 50% inhibitory concentrations (IC50) and superior anticancer efficacy compared to corresponding monotherapies [1]. This suggests that both MAIA-2022-12 and MAIA-2021-20 are promising candidates for future preclinical and clinical studies.

The company plans to advance at least one of these candidates into human clinical trials upon completion of required Good Laboratory Practice (GLP)-toxicity and other evaluations. MAIA Biotechnology is focused on developing targeted immunotherapies for cancer and has a lead program centered around ateganosine, a first-in-class telomere-targeting agent in clinical development for the treatment of non-small cell lung cancer (NSCLC) [2].

MAIA Biotechnology's announcement underscores the company's progress in its second-generation telomere targeting program, which has developed more than 80 ateganosine-like compounds. The publication in a high-impact scientific journal further validates the company's research and development efforts, positioning MAIA Biotechnology as a key player in the immuno-oncology landscape.

References:
[1] https://www.morningstar.com/news/business-wire/20250717795359/maia-biotechnology-announces-peer-reviewed-journal-publication-of-data-validating-second-generation-ateganosine-prodrugs-for-anticancer-therapy
[2] https://ir.maiabiotech.com/news-events/press-releases/detail/145/maia-biotechnology-announces-peer-reviewed-journal